Immutep to Participate in Upcoming Investor Conferences
Immutep to Participate in Upcoming Investor Conferences
SYDNEY, AUSTRALIA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its management will present at the following investor conferences:
澳洲悉尼，2024年8月7日(GLOBE NEWSWIRE)—— Immutep有限公司 ASX:IMM；纳斯达克：IMMP)（“Immutep”或“公司”）是一家临床阶段的生物技术公司，致力于开发新型LAG-3免疫疗法治疗癌症和自身免疫性疾病。今天宣布公司管理层将在以下投资者会议上发表演讲:
| Canaccord Genuity 44th Annual Growth Conference | |
| Location: | InterContinental Boston Hotel, Boston, MA |
| Date: | Wednesday, 14 August 2024 |
| Time: | 08:30am – 8:55am ET |
| Baird 2024 Global Healthcare Conference | |
| Location: | InterContinental NY Barclay, New York, NY |
| Date: | Tuesday, 10 September 2024 |
| Time: | 01:25pm – 1:55pm ET |
| 加拿大皇家证券第44届增长会议 | |
| 位置： | 美国马萨诸塞州波士顿洲际酒店 |
| 日期: | 2024年8月14日，星期三 |
| 时间: | 东部时间早上08:30至08:55 |
| 贝尔德2024全球医疗保健大会 | |
| 位置： | 纽约市洲际巴克莱酒店 |
| 日期: | 2024年9月10日星期二 |
| 时间： | 东部时间下午1:25至1:55 |
A live webcast and replay of the presentation at the Canaccord Genuity conference will be available here and on the Events page within the Investors & Media section of Immutep's website.
Canaccord Genuity会议演讲的现场网络播放和重播将在此处提供： 投资者和媒体部分的活动页面。Immutep网站。 关于Immutep
About Immutep
Immutep is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit .
Immutep是一家临床阶段的生物技术公司，致力于开发新型LAG-3免疫疗法治疗癌症和自身免疫性疾病。我们是在深入了解和推进与淋巴细胞激活基因-3（LAG-3）相关的治疗方案方面的先驱者，我们多元化的产品组合利用其唯一的刺激或抑制免疫反应的能力。Immutep致力于利用其专业知识为有需要的患者带来创新的治疗选择，并为股东创造最大化的价值。有关更多信息，请访问
澳大利亚投资者/媒体： .
Australian Investors/Media:
Catherine Strong, Sodali & Co
+61 (0)406 759 268; catherine.strong@sodali.com
无
Catherine Strong，Sodali & Co
+61 (0)406 759 268; catherine.strong@sodali.com
U.S. Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com
美国媒体:
Chris Basta，投资者关系和企业通信副总裁
+1 (631) 318 4000; chris.basta@immutep.com
